How much revenue does Genomictree make?

Genomictree reported 3.76 billion KRW in revenue for fiscal year 2025, up 59.2% from 2.36 billion KRW in fiscal year 2024. In Q1 2026 revenue was 381.61 million KRW.

What is Genomictree's largest business segment?

Cancer Molecular Diagnosis Business, with 2.20 billion KRW or 93% of segment revenue in fiscal year 2024. Next: Genomic Analysis and Other Business (7%).

Where does Genomictree make most of its revenue?

Korea: 99% of revenue by region in fiscal year 2024, followed by Others (1%).

What companies are similar to Genomictree?

Listed companies of a similar size in the same industry (DNA testing equipment) include Seegene, Inc. (096530.KQ), Gencurix Inc. (229000.KQ), Genesystem Co., Ltd. (363250.KQ), GeneMatrix Inc. (109820.KQ).

Genomictree Inc. (228760.KQ) Stock

About Genomictree Inc.

Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B...

At a glance

Genomictree reported revenue of 3.76 billion KRW for fiscal year 2025, up 59.2% from fiscal year 2024, and net income of -8.99 billion KRW. In Q1 2026 (the quarter ended March 31, 2026) revenue was 381.61 million KRW, up 20.6% from a year before. Its largest business segment, Cancer Molecular Diagnosis Business, brought in 93% of segment revenue in fiscal year 2024; Korea was the largest region with 99%.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.